Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Cash and Equivalents of $28.49 million for fiscal year 2025.
Corbus Pharmaceuticals Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $28.49M | +65.7% |
| 2024 | $17.20M | +25.3% |
| 2023 | $13.72M | -19.3% |
| 2022 | $17.00M | -32.0% |
| 2021 | $25.01M | -70.7% |
| 2020 | $85.43M | +169.1% |
| 2019 | $31.75M | -24.0% |
| 2018 | $41.75M | -33.2% |
| 2017 | $62.54M | +317.1% |
| 2016 | $14.99M | +21.5% |
| 2015 | $12.34M | +97.0% |
| 2014 | $6.26M | +1966.7% |
| 2013 | $303.0K | -44.1% |
| 2012 | $542.5K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.98M | +38.9% | +34.6% |
| June 30, 2025 | $20.04M | -15.4% | +6.1% |
| March 31, 2025 | $18.90M | +34.0% | +9.9% |
| December 31, 2024 | $17.20M | +25.3% | -11.5% |
| September 30, 2024 | $19.42M | +72.7% | -18.0% |
| June 30, 2024 | $23.69M | +183.7% | +67.9% |
| March 31, 2024 | $14.10M | +92.5% | +2.8% |
| December 31, 2023 | $13.72M | -19.3% | +22.0% |
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +65.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Corbus Pharmaceuticals Holdings, Inc.’s cash and equivalents has grown by 5152.1% (from $542.5 thousand to $28.49 million).
- The most recent figure is from Corbus Pharmaceuticals Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: